Carbonic Anhydrase IX Is Not an Independent Predictor of Outcome for Patients With Clear Cell Renal Cell Carcinoma

American Society of Clinical Oncology (ASCO) - Tập 25 Số 30 - Trang 4757-4764 - 2007
Bradley C. Leibovich1, Yuri Sheinin1, Christine M. Lohse1, R. Houston Thompson1, John C. Cheville1, J Závada1, Eugene D. Kwon1
1From the Departments of Urology, Health Sciences Research, Laboratory Medicine and Pathology, and Immunology, Mayo Medical School and Mayo Clinic, Rochester, MN; and the Institute of Organic Chemistry and Biochemistry, Prague, Czech Republic

Tóm tắt

Purpose Expression of carbonic anhydrase IX (CAIX) has been reported to be an independent predictor of outcome and is being investigated as a therapeutic target for patients with clear cell renal cell carcinoma (ccRCC). We attempted to validate the prognostic utility of CAIX expression using a large cohort of ccRCC patients with long-term follow-up. Patients and Methods We identified 730 patients with unilateral, sporadic ccRCC treated surgically between 1990 and 1999. Anti-CAIX monoclonal antibody (clone M75) was used, and tumor specimens were blindly scored for expression levels. Associations of CAIX expression with RCC death were evaluated using Cox proportional hazards regression models. Results There were 241 RCC deaths and a median of 9.4 years of follow-up for patients still under observation. CAIX was expressed in 708 (97.0%) of the specimens; 163 tumors (22.3%) exhibited low (≤ 85% tumor cells positive) expression, and 567 (77.7%) exhibited high (> 85% tumor cells positive) expression. Univariately, low CAIX expression was associated with increased risk of RCC death relative to high expression (risk ratio = 1.65; P < .001). However, low CAIX expression was not associated with RCC death after adjusting for nuclear grade or coagulative tumor necrosis. Additionally, we observed CAIX expression in a number of extrarenal organs. Conclusion CAIX is strongly expressed by ccRCC. Although CAIX is associated with outcome in patients with ccRCC, it is not an independent prognostic marker. Furthermore, CAIX expression is apparent in extrarenal organs. As such, exploitation of CAIX as a prognostic marker and therapeutic target merits additional consideration.

Từ khóa


Tài liệu tham khảo

10.1097/00000478-200203000-00001

10.1097/00000478-200305000-00005

10.1016/S0022-5347(05)64153-5

10.1097/01.ju.0000095475.12515.5e

10.1002/cncr.11234

10.1097/01.ju.0000177487.64651.3a

10.1200/JCO.1999.17.8.2530

Liao SY, Aurelio ON, Jan K, et al: Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 57:2827,1997-2831,

Bui MHT, Seligson D, Han K-r, et al: Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res 9:802,2003-811,

10.1158/1078-0432.CCR-04-2019

10.1158/1078-0432.CCR-1004-0010

Divgi CR, Bander NH, Scott AM, et al: Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 4:2729,1998-2739,

Oosterwijk E, Debruyne FM, Schalken JA: The use of monoclonal antibody G250 in the therapy of renal-cell carcinoma. Semin Oncol 22:34,1995-41,

10.1016/S0022-5347(01)69131-6

Tso CL, Zisman A, Pantuck A, et al: Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Cancer Res 61:7925,2001-7933,

10.1038/sj.bjc.6690757

10.1016/S0022-5347(05)00040-6

10.1097/01.ju.0000116444.08690.e2

10.1097/00000478-199706000-00001

10.1002/1097-0142(20000801)89:3<604::AID-CNCR16>3.0.CO;2-Q

10.1002/cncr.21206

10.1016/S0002-9440(10)64038-2

10.1073/pnas.95.21.12596

10.1073/pnas.040554897

10.1054/bjoc.2000.1111

Liao SY, Brewer C, Zavada J, et al: Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am J Pathol 145:598,1994-609,

Loncaster JA, Harris AL, Davidson SE, et al: Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: Correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61:6394,2001-6399,

10.1002/ijc.2910540218

10.1200/JCO.2001.19.6.1649

10.1002/cncr.21127

10.1097/00000478-200404000-00002

Divgi CR, O'Donoghue JA, Welt S, et al: Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med 45:1412,2004-1421,

10.1038/sj.bjc.6601617

Varga Z, de Mulder P, Kruit W, et al: A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients. Folia Biol (Praha) 49:74,2003-77,

10.1097/00006231-200203000-00005

Steffens MG, Boerman OC, de Mulder PH, et al: Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clinical Cancer Res 5:3268s,1999-3274s,

10.1200/JCO.1997.15.4.1529

Oosterwijk E, Debruyne FM: Radiolabeled monoclonal antibody G250 in renal-cell carcinoma. World J Urol 13:186,1995-190,

10.1200/JCO.1993.11.4.738

10.1016/S0022-5347(05)68265-1

Dechet CB, Zincke H, Sebo TJ, et al: Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults. J Urol 169:71,2003-74,

Thông tin
Thông tin xuất bản

American Society of Clinical Oncology (ASCO)

Tập 25 Số 30

4757-4764

Thông tin tác giả